JZP441
Phase 1Small molecule
Jazz PharmaceuticalsJZP441 is one of 7 small molecule programs targeting Narcolepsy. It is currently in Phase 1.
1
Indications
3
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
9 competitors in Narcolepsy
#DrugCompanyPhaseTrials
1Biaxin
AbbVieApproved
Romazicon
CConrado Roberto Hoffmann Filho
Approved
E2086
EisaiPhase 2
Xyrem
Jazz PharmaceuticalsPreclinical
Wakix
HHarmony Biosciences Management, Inc.
Preclinical
Lu AH69593
LundbeckPhase 1
JZP441
Jazz PharmaceuticalsPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Narcolepsy1 trial
Tics1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for JZP441. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company